Cargando…

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

Treatment with 5α‐reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Tsen‐Fang, Choi, Gwang Seong, Kim, Beom Joon, Kim, Moon‐Bum, Ng, Chi Fai, Kochhar, Puja, Jasper, Stacy, Brotherton, Betsy, Orban, Barbara, Lulic, Zrinka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055634/
https://www.ncbi.nlm.nih.gov/pubmed/29667763
http://dx.doi.org/10.1111/1346-8138.14329
_version_ 1783341212609019904
author Tsai, Tsen‐Fang
Choi, Gwang Seong
Kim, Beom Joon
Kim, Moon‐Bum
Ng, Chi Fai
Kochhar, Puja
Jasper, Stacy
Brotherton, Betsy
Orban, Barbara
Lulic, Zrinka
author_facet Tsai, Tsen‐Fang
Choi, Gwang Seong
Kim, Beom Joon
Kim, Moon‐Bum
Ng, Chi Fai
Kochhar, Puja
Jasper, Stacy
Brotherton, Betsy
Orban, Barbara
Lulic, Zrinka
author_sort Tsai, Tsen‐Fang
collection PubMed
description Treatment with 5α‐reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and associated treatment discontinuations, in men treated with dutasteride for androgenetic alopecia. Participants were randomized to receive double‐blind dutasteride 0.5 mg or placebo once daily for 24 weeks, followed by open‐label dutasteride 0.5 mg for an additional 24 weeks. Sexual adverse events were followed up until resolution or for up to 24 weeks after the last dose. Overall, 117 men, 23–50 years of age, were randomized. The incidence of sexual adverse events was approximately twofold higher in the dutasteride group (16%) than the placebo group (8%) during the double‐blind period; the overall incidence of sexual adverse events was lower (5%) during the open‐label period. All adverse events were mild to moderate in severity and considered treatment‐related. The adverse events resolved while on study treatment or after the end of treatment and did not lead to treatment discontinuation. A limitation of this study was the small sample size. The sexual adverse events of impotence, decreased libido and ejaculation disorders reported in this study were expected and reversible.
format Online
Article
Text
id pubmed-6055634
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60556342018-07-23 Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia Tsai, Tsen‐Fang Choi, Gwang Seong Kim, Beom Joon Kim, Moon‐Bum Ng, Chi Fai Kochhar, Puja Jasper, Stacy Brotherton, Betsy Orban, Barbara Lulic, Zrinka J Dermatol Original Articles Treatment with 5α‐reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and associated treatment discontinuations, in men treated with dutasteride for androgenetic alopecia. Participants were randomized to receive double‐blind dutasteride 0.5 mg or placebo once daily for 24 weeks, followed by open‐label dutasteride 0.5 mg for an additional 24 weeks. Sexual adverse events were followed up until resolution or for up to 24 weeks after the last dose. Overall, 117 men, 23–50 years of age, were randomized. The incidence of sexual adverse events was approximately twofold higher in the dutasteride group (16%) than the placebo group (8%) during the double‐blind period; the overall incidence of sexual adverse events was lower (5%) during the open‐label period. All adverse events were mild to moderate in severity and considered treatment‐related. The adverse events resolved while on study treatment or after the end of treatment and did not lead to treatment discontinuation. A limitation of this study was the small sample size. The sexual adverse events of impotence, decreased libido and ejaculation disorders reported in this study were expected and reversible. John Wiley and Sons Inc. 2018-04-18 2018-07 /pmc/articles/PMC6055634/ /pubmed/29667763 http://dx.doi.org/10.1111/1346-8138.14329 Text en © 2018 GlaxoSmithKline. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Tsai, Tsen‐Fang
Choi, Gwang Seong
Kim, Beom Joon
Kim, Moon‐Bum
Ng, Chi Fai
Kochhar, Puja
Jasper, Stacy
Brotherton, Betsy
Orban, Barbara
Lulic, Zrinka
Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
title Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
title_full Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
title_fullStr Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
title_full_unstemmed Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
title_short Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
title_sort prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055634/
https://www.ncbi.nlm.nih.gov/pubmed/29667763
http://dx.doi.org/10.1111/1346-8138.14329
work_keys_str_mv AT tsaitsenfang prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT choigwangseong prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT kimbeomjoon prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT kimmoonbum prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT ngchifai prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT kochharpuja prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT jasperstacy prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT brothertonbetsy prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT orbanbarbara prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia
AT luliczrinka prospectiverandomizedstudyofsexualfunctioninmentakingdutasterideforthetreatmentofandrogeneticalopecia